Bharat Biotech’s Covaxin vaccine yields positive Phase I data
This is Great News! Yes, Sir! Yes, Ma’am! Great News from India! What impresses me the most is Two-Fold. First-No Adverse Effects on the Test Subjects. Second-the large number of Test Subjects in Phase I is very, very impressive! I can’t wait to see how well Phase II-III go. I’m very excited for all Indians. This maybe the right one for the World. Good Luck!
Here’s an Exert-
Sign up here for GlobalData’s free bi-weekly Covid-19 report on the latest information your industry needs to know.
India-based Bharat Biotech’s Covid-19 vaccine candidate, Covaxin, has demonstrated an encouraging safety profile in a Phase I clinical trial conducted in the country.
Developed in alliance with the Indian Council of Medical Research (ICMR) – National Institute of Virology (NIV), Covaxin is an inactivated vaccine candidate.
India’s regulatory agency granted approval for Phase I and II trials of the vaccine in June.
According to local media reports, preliminary Phase I trial results showed that the vaccine is safe. The trial’s principal investigator Dr Savita Verma at Post-Graduate Institute (PGI) of Medical Sciences, Rohtak said that no adverse events were reported in subjects vaccinated at the site.